藥物交互作用
Atorvastatin + Niacin
嚴重程度: 中度
Atorvastatin and Niacin: moderate interaction.
最後更新
僅供醫療專業人員參考。本頁為簡要摘要，並非醫療建議，亦不能取代官方仿單或臨床判斷。開立處方或調劑前請務必核實。
本頁的臨床內容僅提供英文版。
摘要
Lipid-modifying doses of niacin may add to the myopathy risk of atorvastatin. Cases of muscle toxicity have been reported, though the overall risk is low.
用白話說明這項交互作用的意義
Atorvastatin and Niacin can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Atorvastatin belongs to Cardiovascular; Niacin belongs to Cardiovascular.
為什麼會發生
Additive myotoxicity; niacin may also have a minor pharmacokinetic effect.
處置方式
Counsel patients to report muscle pain or weakness and check CK when symptomatic. Use the lowest effective doses.
可向藥師詢問的問題
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Atorvastatin 的其他交互作用
Niacin 的其他交互作用
常見問題
Can I take Atorvastatin with Niacin?
MediHelp rates the interaction as moderate. Atorvastatin and Niacin can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Lipid-modifying doses of niacin may add to the myopathy risk of atorvastatin. Cases of muscle toxicity have been reported, though the overall risk is low.
How serious is the interaction between Atorvastatin and Niacin?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Counsel patients to report muscle pain or weakness and check CK when symptomatic. Use the lowest effective doses.
What other medicines interact with Atorvastatin?
MediHelp also lists interactions of Atorvastatin with, for example, Tipranavir, Atazanavir, Clarithromycin. The full list is on the Atorvastatin page.
在 MediHelp App 中取得完整藥品專論、劑量資訊與交互作用檢查
在 MediHelp App 中開啟完整參考資料、檢查多種藥物間的交互作用，並使用劑量工具。
